Therapy Acceleration Program

Introducing the Therapy Acceleration Program (TAP) by The Leukemia & Lymphoma Society (LLS)—a groundbreaking initiative driving innovation and transformation in the realm of blood cancer therapeutics. Established as a strategic venture philanthropy initiative in 2007, LLS TAP is on a mission to accelerate the development of cutting-edge therapies, pushing the boundaries of what's possible and striving to redefine the standard of care for patients with rare blood cancers.

At the core of TAP's mission is a commitment to collaboration with biotech companies. By strategically partnering with these entities, TAP provides crucial support for the development of novel platforms and first-in-class assets, specifically addressing unmet medical needs, emerging patient populations, and rare blood cancers. Not only does TAP aim to revolutionize treatment options, but it also seeks to generate a tangible return on investment, further fueling the LLS Mission.

Join us in this transformative journey as LLS TAP pioneers strategic venture philanthropy to bring about meaningful change in the landscape of blood cancer therapeutics. Together, we can accelerate progress, improve outcomes, and ultimately transform the lives of those affected by rare blood cancers.